Abstract: The invention relates to topical ophthalmic preparations in eye drops containing bimatoprost as an active ingredient at the concentration of 0.1 mg/ml, wherein the presence of benzalkonium chloride is limited to the indispensable minimum commonly required for its activity as an antimicrobial preservative, i.e. from 50 at 80 ppm, and the bioavailability of the product is ensured by the addition of specific non-ionic surfactants, i.e., poloxamers.

Abstract: Ophthalmic solutions containing arabinogalactans with a protective activity on the corneal epithelium, particularly suitable for use as artificial tears stimulating the recovery of corneal lesions and also particularly useful for contact lens users, containing from 1% to 10% by weight of arabinogalactan in an aqueous solution and possible other excipients, among which tonicity-adjusting agents, pH correctors, buffers and preservatives, except for benzalkonium chloride. The compositions according to the invention have a virtually negligible viscosity, but are sufficiently mucoadhesive to assure a considerable permanence time in the area of application. Besides being well-tolerated, the aforesaid compositions have considerable re-epithelization capacity.

Abstract: Ophthalmic solutions containing arabinogalactans with a protective activity on the corneal epithelium, particularly suitable for use as artificial tears stimulating the recovery of corneal lesions and also particularly useful for contact lens users, containing from 1% to 10% by weight of arabinogalactan in an aqueous solution and possible other excipients, among which tonicity-adjusting agents, pH correctors, buffers and preservatives, except for benzalkonium chloride. The compositions according to the invention have a virtually negligible viscosity, but are sufficiently mucoadhesive to assure a considerable permanence time in the area of application. Besides being well-tolerated, the aforesaid compositions have considerable re-epithelisation capacity.

Abstract: An ophthalmic pharmaceutical composition containing acetylcysteine as the active ingredient having a mucolitic action, suitable for administration in eyedrops, where N-acetyl-cysteine is neutralised with base DEAE-dextrane in order to reach pH levels preferably between 6.0 and 7.5, and having a physiologically acceptable osmolarity less than 320 mOsm/kg. The presence of a neutralising agent for N-acetyl-cysteine that does not negatively affect the composition osmolarity allows the formulation to be isotonic or even hypotonic, thus avoiding the irritative and potentially damaging effects of previous ophthalmic products containing N-acetyl-cysteine.

Abstract: An ophthalmic pharmaceutical composition containing acetylcysteine as the active ingredient having a mucolitic action, suitable for administration in eyedrops, where N-acetyl-cysteine is neutralised with base DEAE-dextrane in order to reach pH levels preferably between 6.0 and 7.5, and having a physiologically acceptable osmolarity less than 320 mOsm/kg. The presence of a neutralising agent for N-acetyl-cysteine that does not negatively affect the composition osmolarity allows the formulation to be isotonic or even hypotonic, thus avoiding the irritative and potentially damaging effects of previous ophthalmic products containing N-acetyl-cysteine.

Abstract: The polysaccharide fraction of tamarind gum, a product of natural origin obtained from the seeds of Tamarindus indica, is used for the production of a thickened ophthalmic solution having a pseudoplastic rheological behaviour and mucoadhesive properties. Said solution is useful as artificial tear and as vehicle for sustained release ophthalmic drugs. The concentrations of tamarind seed polysaccharide preferably employed in ophthalmic preparations for use as artificial tears, i.e. as products for replacing and stabilising the natural tear fluid, particularly indicated for the treatment of dry eye syndrome, are comprised between 0.7 and 1.5% by weight. The concentrations of tamarind seed polysaccharide preferably employed in the production of vehicles (i.e. delivery systems) for ophthalmic drugs, having the function of prolonging the permanence time of said medicaments at their site of action, are comprised between 1 and 4% by weight.